Adma Biologics (ADMA) Common Equity (2011 - 2025)

Adma Biologics' Common Equity history runs 15 years deep, the most recent figure standing at $477.3 million for Q4 2025.

• Quarterly Common Equity rose 36.76% year-over-year to $477.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $477.3 million (up 36.76% YoY) and the FY2025 annual result came in at $477.3 million, up 36.76% from the prior year.
• Common Equity was $477.3 million for Q4 2025 at Adma Biologics, up from $431.2 million in the prior quarter.
• Across five years, Common Equity topped out at $477.3 million in Q4 2025 and bottomed at $100.4 million in Q3 2022.
• A 5-year average of $207.2 million and a median of $149.1 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity decreased 11.03% — and 2024, when it soared 158.14%.
• Adma Biologics' Common Equity stood at $141.2 million in 2021, then advanced by 7.65% to $152.0 million in 2022, then slipped by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024, then soared by 36.76% to $477.3 million in 2025.
• Business Quant data shows ADMA's Common Equity at $477.3 million in Q4 2025, $431.2 million in Q3 2025, and $398.3 million in Q2 2025.